Kirkland & Ellis represented the joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China, on the Hong Kong Exchanges and Clearing Limited on September 5, 2023.
ImmuneOnco is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. The IPO raised approximately $40.7 million. The joint sponsors are Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited.
The Kirkland team was led by capital markets partner Mengyu Lu, with support from capital markets partner Samantha Peng.